Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is based in Philadelphia, Pennsylvania. Show more
Location: One Commerce Square, Philadelphia, PA, 19103, United States | Website: https://www.passagebio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
22.65M
52 Wk Range
$5.12 - $26.60
Previous Close
$7.12
Open
$7.11
Volume
24,367
Day Range
$6.90 - $7.20
Enterprise Value
-10.25M
Cash
57.63M
Avg Qtr Burn
-9.017M
Insider Ownership
0.21%
Institutional Own.
54.51%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PBFT02 (AAV1) Details Neurological disorder, Frontotemporal dementia | Phase 1/2 Data readout | |
PBGM01 (AAVhu68 viral vector) Details Rare genetic disease, Neurological disorder | Failed Discontinued |